Bupivacaine is a local anesthetic used to numb specific areas of the body during medical procedures or surgery, and can also be used to relieve pain after surgery or for chronic pain conditions.[2] Marcaine is currently approved and in use across 119 indications[4].[1]
Marcaine is one of 1442 small molecule programs targeting Plantar Fasciitis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
Marcaine
Trodelvy
Halaven
Tecentriq
Megace
Methylthioninium Chloride
MS Contin
Aquasol E
QS21
Dextromethorphan Hydrobromide
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
BUPIVACAINE HYDROCHLORIDE
NDA NDA018053
Jan 1, 1982
MARCAINE HYDROCHLORIDE
NDA NDA016964
Jan 1, 1982
SENSORCAINE
NDA NDA018304
May 4, 1984
MARCAINE
NDA NDA018692
Sep 3, 1992
BUPIVACAINE HYDROCHLORIDE KIT
NDA NDA019978
Oct 28, 2011
EXPAREL
NDA NDA022496
Aug 28, 2020
XARACOLL
NDA NDA209511
Feb 1, 2021
POSIMIR
NDA NDA204803
Sources
Details
Patent Cliff
May 20, 2029
Earliest patent expiration — generic entry possible after this date